A new method for the quantitative analysis by liquid chromatography-tandem mass spectrometry ( LC-MS/MS ) of five tyrosine kinase inhibitors ( afatinib , crizotinib , osimertinib , erlotinib and nintedanib ) used in the treatment of non-small cell lung cancer ( NSCLC ) was developed and validated in human plasma .
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.  A new method for the quantitative analysis by liquid chromatography-tandem mass spectrometry ( LC-MS/MS ) of five tyrosine kinase inhibitors ( afatinib , crizotinib , osimertinib , erlotinib and nintedanib ) used in the treatment of non-small cell lung cancer ( NSCLC ) was developed and validated in human plasma . Separation was performed on an Accucore
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.  A new method for the quantitative analysis by liquid chromatography-tandem mass spectrometry ( LC-MS/MS ) of five tyrosine kinase inhibitors ( afatinib , crizotinib , osimertinib , erlotinib and nintedanib ) used in the treatment of non-small cell lung cancer ( NSCLC ) was developed and validated in human plasma . Separation was performed on an Accucore

            ### Response:
            afatinib, crizotinib, osimertinib, erlotinib, nintedanib
            